Actively Recruiting
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
Led by Medical College of Wisconsin · Updated on 2026-01-26
1100
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating whether small differences in genes affecting the development and function of certain organs increase the risk of chronic lung disease and other serious conditions in very low birth weight infants, such as necrotizing enterocolitis, sepsis, patent ductus arteriosus, and intraventricular hemorrhage. This study focuses on understanding how genetic variations, especially in toll like receptor genes that play a role in the immune system, interact with other genes to influence these risks. The study involves analyzing blood samples from very low birth weight infants (under 1500 grams at birth) to detect known and new genetic variations in specific genes related to immune defense and organ repair. Researchers will also measure levels of biomarkers like cytokines, micro-RNAs, and peptides in the blood that may reflect inflammation or healing processes. These genetic and biomarker data will be compared between infants who develop these diseases and those who do not. Participants will have small blood samples collected for DNA and biomarker testing, with follow-up during their hospital stay averaging 6 to 8 weeks. The study will monitor the development of chronic lung disease and other prematurity-related conditions, aiming to improve early identification and understanding of disease progression. This research may help develop better strategies to prevent these complications in premature infants.
CONDITIONS
Brief Title
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Infants born weighing less than 1500 grams
You will not qualify if you...
- Infants born with congenital heart disease (other than patent ductus arteriosus)
- Major congenital anomalies of the gastrointestinal tract, respiratory tract, or kidneys
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 6 to 8 weeks (average hospital stay)
Participants have small blood samples collected for genetic analysis and biomarker measurement. They are observed during their hospital stay to assess the development of diseases of prematurity such as chronic lung disease and sepsis.
Blood samples collected once or twice during hospital stay
Trial Site Locations
Total: 1 location
1
Children's Wisconsin
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
G
G. Ganesh Konduri, MD
K
Kathleen M Meskin, BSN
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here